Dongsheng Tu
Dongsheng Tu is the statistician behind decades of CCTG trials, including the erlotinib and cetuximab studies that changed lung and colorectal cancer care.
Dongsheng Tu has been senior biostatistician for Canadian Cancer Trials Group studies including BR.21 (erlotinib in NSCLC) and CO.17 (cetuximab in colorectal cancer), and contributes to methodology for adaptive and biomarker-driven trials.
| Title | Journal | Year |
|---|---|---|
| Cetuximab for the treatment of colorectal cancer (CO.17) | NEJM | 2007 |
Pages like this
not linked directly; found by shared links- PersonCarsten Bokemeyer
Shares Cetuximab, Colorectal cancer.
- InstitutionCancer Care Alberta (Alberta Health Services)
Shares Canadian Cancer Trials Group (CCTG), Colorectal cancer.
- PersonVolker Heinemann
Shares Cetuximab, Colorectal cancer.
- PersonRyan B. Corcoran
Shares Cetuximab, Colorectal cancer.
- InstitutionThe Ottawa Hospital Cancer Centre / Ottawa Hospital Research Institute
Shares Canadian Cancer Trials Group (CCTG), Colorectal cancer.
- PersonJosep Tabernero
Shares Cetuximab, Colorectal cancer.
- PairingAnti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC
Shares Cetuximab, Colorectal cancer.
- Key paperCHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer
Shares Canadian Cancer Trials Group (CCTG), Colorectal cancer.